Xinan Sheng
About
Xinan Sheng is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Xinan Sheng has authored 192 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Oncology, 89 papers in Molecular Biology and 48 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xinan Sheng's work include Cancer Immunotherapy and Biomarkers (57 papers), Cutaneous Melanoma Detection and Management (56 papers) and Melanoma and MAPK Pathways (47 papers). Xinan Sheng is often cited by papers focused on Cancer Immunotherapy and Biomarkers (57 papers), Cutaneous Melanoma Detection and Management (56 papers) and Melanoma and MAPK Pathways (47 papers). Xinan Sheng collaborates with scholars based in China, Ethiopia and United States. Xinan Sheng's co-authors include Lu Si, Chuanliang Cui, Zhihong Chi, Jun Guo, Yan Kong, Bin Lian, Lili Mao, Jie Dai, Bixia Tang and Xieqiao Yan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.
In The Last Decade
Xinan Sheng
181 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Xinan Sheng China | 30 | 2.2k | 1.5k | 736 | 493 | 485 | 192 | 3.3k | ||
| Chuanliang Cui China | 28 | 2.0k 0.9× | 1.4k 0.9× | 667 0.9× | 385 0.8× | 340 0.7× | 151 | 2.9k | ||
| Josep M. Piulats Spain | 30 | 1.5k 0.7× | 1.1k 0.7× | 894 1.2× | 847 1.7× | 316 0.7× | 162 | 3.2k | ||
| Rom S. Leidner United States | 27 | 2.4k 1.1× | 965 0.6× | 1.5k 2.0× | 576 1.2× | 475 1.0× | 94 | 3.7k | ||
| Asma Tulbah Saudi Arabia | 31 | 1.9k 0.9× | 880 0.6× | 765 1.0× | 533 1.1× | 330 0.7× | 104 | 3.3k | ||
| David Gyorki Australia | 22 | 2.1k 1.0× | 1.2k 0.8× | 577 0.8× | 459 0.9× | 174 0.4× | 109 | 3.0k | ||
| Alexander N. Shoushtari United States | 34 | 3.3k 1.5× | 1.4k 0.9× | 1.6k 2.1× | 833 1.7× | 315 0.6× | 167 | 4.7k | ||
| Adriano Piris United States | 27 | 2.0k 0.9× | 1.8k 1.2× | 606 0.8× | 369 0.7× | 395 0.8× | 69 | 3.5k | ||
| Sapna P. Patel United States | 29 | 1.8k 0.8× | 1.5k 1.0× | 1.2k 1.7× | 473 1.0× | 159 0.3× | 210 | 3.6k | ||
| Scott S. Tykodi United States | 28 | 1.9k 0.8× | 1.2k 0.8× | 944 1.3× | 1.2k 2.5× | 299 0.6× | 106 | 3.1k | ||
| Zeynep Eroglu United States | 26 | 2.8k 1.3× | 1.2k 0.8× | 1.1k 1.5× | 557 1.1× | 116 0.2× | 124 | 3.7k |
Countries citing papers authored by Xinan Sheng
Since
Specialization
Citations
This map shows the geographic impact of Xinan Sheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinan Sheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinan Sheng more than expected).
Fields of papers citing papers by Xinan Sheng
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Xinan Sheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinan Sheng. The network helps show where Xinan Sheng may publish in the future.
Co-authorship network of co-authors of Xinan Sheng
This figure shows the co-authorship network connecting the top 25 collaborators of Xinan Sheng. A scholar is included among the top collaborators of Xinan Sheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinan Sheng. Xinan Sheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gao, Jingtao, Xin Yue, Xinan Sheng, et al.. (2025). Liver-specific Bcl3 Knockout Alleviates Acetaminophen-induced Liver Injury by Activating Nrf2 Pathway in Male Mice. Cellular and Molecular Gastroenterology and Hepatology. 19(6). 101483–101483.
2.
Zhang, Fenghao, Qian Guo, Zhihong Chi, et al.. (2025). Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian. Journal of genetics and genomics. 52(4). 525–538.
3.
Zeng, Hao, Xingming Zhang, Jiayu Liang, et al.. (2024). Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).. Journal of Clinical Oncology. 42(16_suppl). 4523–4523.
4.
Sheng, Xinan, Hongqian Guo, Xin Yao, et al.. (2024). Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study.. Journal of Clinical Oncology. 42(16_suppl). 4537–4537.
5.
Tang, Bixia, Rong Duan, Xieqiao Yan, et al.. (2024). Natural history of bone-only metastasis in renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 42(4). 119.e17–119.e22.
6.
Zhou, Li, Kun Yang, Xieqiao Yan, et al.. (2024). Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study. Annals of Oncology. 36(3). 331–339.
7.
Liu, Teli, Siming Li, Xiaokun Ma, et al.. (2023). An iodine‑labelled Antibody–drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma. International Journal of Pharmaceutics. 651. 123756–123756.
8.
Duan, Xiaojiang, Lei Xia, Martin G. Pomper, et al.. (2023). First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma. Clinical Cancer Research. 29(17). 3395–3407.
9.
Cui, Chuanliang, Yu Chen, Zhiguo Luo, et al.. (2023). Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study. BMC Cancer. 23(1). 121–121.
10.
Cui, Chuanliang, Xuan Wang, Bin Lian, et al.. (2022). OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study. Journal for ImmunoTherapy of Cancer. 10(4). e004307–e004307.
11.
Li, Siming, Xiaowen Wu, Xieqiao Yan, et al.. (2022). Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. Journal for ImmunoTherapy of Cancer. 10(2). e004036–e004036.
12.
Xu, Tianxiao, Jie Dai, Lu Si, et al.. (2021). EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma. Journal of Investigative Dermatology. 142(4). 1158–1170.e8.
13.
Yan, Xieqiao, Xinan Sheng, Zhihong Chi, et al.. (2021). Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology. 39(8). 881–889.
14.
Chen, Huijing, Xinan Sheng, Beibei Hu, et al.. (2020). Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with refractory/metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study. European Urology Open Science. 19. e1579–e1579.
15.
Xu, Tianxiao, Sifan Yu, Meng Ma, et al.. (2018). cMET-N375S germline mutation is associated with poor prognosis of melanoma in Chinese patients. Translational Cancer Research. 7(2). 248–256.
16.
Bai, Xue, Yan Kong, Zhihong Chi, et al.. (2017). MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical Cancer Research. 23(20). 6120–6127.
17.
Kong, Yan, Lu Si, Yiqian Li, et al.. (2015). Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors. Clinical Cancer Research. 22(4). 1018–1027.
18.
Dai, Jie, Yan Kong, Lu Si, et al.. (2013). Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib. Clinical Cancer Research. 19(24). 6935–6942.
19.
Lian, Bin, Lu Si, Chuanliang Cui, et al.. (2013). Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 19(16). 4488–4498.
20.
Si, Lu, Yanyan Zhu, Xiaowei Xu, et al.. (2011). Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clinical Cancer Research. 17(7). 1684–1691.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Chuanliang Cui Breakdown of academic impact, for papers by Josep M. Piulats Breakdown of academic impact, for papers by Rom S. Leidner Breakdown of academic impact, for papers by Asma Tulbah Breakdown of academic impact, for papers by David Gyorki Breakdown of academic impact, for papers by Alexander N. Shoushtari Breakdown of academic impact, for papers by Adriano Piris Breakdown of academic impact, for papers by Sapna P. Patel Breakdown of academic impact, for papers by Scott S. Tykodi Breakdown of academic impact, for papers by Zeynep Eroglu